NL
DE
In the American Journal of Respiratory and Critical Care Medicine Lindsey te Brake and colleagues described the shortcomings of a moderate increase in rifampicin dosing, the cornerstone TB drug.
Combined with ongoing trials to optimize the dose of rifampicin ≥35 mg/kg, powerful statistical pooled data analyses will help influence future treatment guidelines and improve the lives of millions of patients with tuberculosis worldwide.
Publication
Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Te Brake LHM, Boeree MJ, Aarnoutse RE.
Lindsey te Brake, Martin Boeree and Rob Aarnoutse are members of theme Infectious diseases and global health.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
NIH grant for follow-up research on tuberculous meningitis
10 February 2022Met subsidie van het Amerikaanse NIH gaat With a grant from the U.S. NIH, Reinout van Crevel will continue to unravel the disease process of tuberculous meningitis.
read more
Antibodies are sustained in nasal fluid after mild corona infection
27 September 2021 Testing through nasal fluids is easier than through blood read more
Less inflammation with a traditional Tanzanian diet than with a Western diet
18 February 2021 Study shows differences between western and traditional diet. read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection
17 February 2021 In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. read more
International grants for tuberculous meningitis research
27 March 2019Meningitis is the most deadly manifestation of tuberculosis. Two grants have been awarded to Radboudumc researchers.
read more